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Abstract 
BACKGROUND: Cytochrome P450 2A6 (CYP2A6) is known as an enzyme which is responsible for the 
metabolism of chemical compounds.  
AIM: This study aimed to analyse the relationship between CYP2A6 gene polymorphism with nicotine metabolism 
rates and lung cancer incidence among smokers of Batak ethnic group in Indonesia. 
METHODS: This study was a case-control study involving 140 research subjects through a purposive sampling 
technique from three hospitals in Medan, Indonesia. An examination of nicotine metabolism rates was conducted 
for all subjects using the 3HC/cotinine ratio parameter with LC-MS/MS technique. The examination of the 
CYP2A6 gene was performed with PCR-RFLP. Data were analysed with Conditional Logistic Regression test 
using Epi Info 7.0 software. 
RESULTS: The allele frequencies of CYP2A6*1A, CYP2A6*1B, and CYP2A6*4A found were 44.3%, 48.9%, and 
6.8%, respectively. The *1B allele showed the highest metabolism rate. It is found that slow metabolizer 
individuals were 5.49 times more likely to develop lung cancer (P = 0.01, 95%CI 1.2-24.8). 
CONCLUSION: Among the Bataknese smokers studied, the CYP2A6*1B allele was found to be the most 
common allele and showed the highest rate of nicotine metabolism. However, the results show the insignificant 
relationship among CYP2A6 genetic polymorphism, nicotine metabolism, and lung cancer incidence. 
 
 
 
 
 
 
 
Introduction 
 
Lung cancer is the largest case of cancer in 
the world with an increased number of patient at 
approximately 1.2 million people/year [1], and it also 
shows an increase in mortality [2].
 
One cause of lung 
cancer is from tobacco smoke because of smoking 
activity with nicotine and nitrosamine as carcinogenic 
substances contained in it [3]. Carcinogenic 
substances in cigarettes require metabolic activation 
which is carried by enzymes in a human body. 
Cytochrome P450 (CYP) is a superfamily of 
heme-containing monooxygenases involved in the 
metabolism of drugs, environmental pollutants, and 
food materials which contain chemical compounds 
and endogenous compounds [4]. Among the family 
genes of CYP2A, only the CYP2A6 gene encodes 
active proteins while the other genes are catalytically 
defective enzymes [5].
 
CYP2A6 gene is also 
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responsible for the metabolism of carcinogenic 
substances of tobacco [6] [7]. 
One way to detect the enzyme capacity of 
CYP2A6 in metabolising tobacco substances, 
especially nicotine, is by investigating the nicotine 
metabolite ratio (NMR) between cotinine (COT) and 
trans-3'-hydroxycotinine (3HC). As known, nicotine in 
tobacco is metabolized into cotinine (COT) and then 
into trans-3'-hydroxycotinin (3HC) by CYP2A6 
enzymes [8] [9].
 
The capacity of CYP2A6 enzyme 
based on NMR can be used to show the levels of 
body needs in maintaining the nicotine levels. In this 
case, there are two types of metabolism which occur, 
namely fast metabolizer and slow metabolizer. The 
fast metabolizer signifies a high level of need in 
maintaining the nicotine levels in the body, so it leads 
to increased consumption of cigarette and a higher 
risk of lung cancer whereas the slow metabolizer 
signifies the opposite [10]. 
Related to the above explanation, several 
studies found that the genetic polymorphisms of 
CYP2A6 have a relationship with nicotine metabolism. 
Su et al., [11] found that enzyme activity was detected 
higher in CYP2A6*1 which indicated a high rate of 
nicotine metabolism. Nakajima et al., [12] revealed a 
large difference in the cotinine ratio of nicotine in 
each.
 
In their follow-up studies, they concluded that 
the difference between individuals in the formation of 
cotinine from nicotine has a strong association with 
the genetic polymorphism of the CYP2A6 gene, and 
this result was found in 92 healthy Japanese. Also, 
another study also detected that there was a 
difference in the nicotine metabolism rate between 
Korean population and the Japanese population [13].
 
Similarly, Caraballo et al. [14] and Peârez-Stable et 
al., [15] found a difference in nicotine metabolism 
between smokers from the Black race and Caucasian 
race. 
Besides the relationship between the genetic 
polymorphism of CYP2A6 and nicotine metabolism, 
Fujieda et al., [16] found that there was a clear 
relationship between the genetic polymorphism of 
CYP2A6 and cancer risk in the Japanese population.
 
Tanner et al., [17] also reported the same findings in 
which they examined the relationship between the 
genetic polymorphism of CYP2A6 with nicotine 
metabolism and the risk of lung cancer in the 
American Indian population. 
However, several other studies found that 
there was no apparent relationship between the 
genetic polymorphism of CYP2A6 with nicotine 
metabolism and the risk of developing lung cancer 
[16] [18] [19] [20] [21].
 
Based on this, further research 
on the relationship between the genetic 
polymorphisms of CYP2A6 with nicotine metabolism 
and the risk of lung cancer in only one ethnic group 
needs to be conducted to obtain more significant 
results. 
Based on the above explanations, this 
research was aimed to investigate the relationship 
between genetic polymorphisms of CYP2A6 in the 
population of Batak ethnic group with nicotine 
metabolism and the risk of developing lung cancer. 
The three allele investigated were CYP2A6*1A, 
CYP2A6*1B, and CYP2A6*4A. This based on the 
study from Oscarson et al., [22] that found those three 
alleles as the most frequent allele in the Asian 
population. Also, the Batak ethnic group was chosen 
due to their tradition to smoke in several traditional 
ceremonies and their pure genetic inheritance. Thus, 
this study would give a more significant model of 
CYP2A6 genetic polymorphisms associated with 
nicotine metabolism and the risk of lung cancer. 
 
 
Methods 
 
This study involved 140 male Bataknese 
smokers which were recruited from Haji Adam Malik 
Hospital, USU Hospital, and Elizabeth Hospital in 
Medan, North Sumatra, Indonesia. The recruited 
subjects were pure descendants of the Batak ethnicity 
whose father, mother, and both grandparents were 
pure Bataknese. All subjects represented 6 sub-
ethnics of Batak (i.e. Karo, Pakpak, Toba, 
Simalungun, Mandailing, and Angkola) [23]. Out of the 
140 subjects, 70 smokers who suffered from lung 
cancer were specified as case samples, and 70 
healthy smokers were specified as control samples. 
All subjects were asked to answer a questionnaire 
which consisted of structured information about 
residence, pedigree chart (three breeds of pure Batak 
ethnicity), occupational history, smoking status, and 
history of cancer in the family (parents and siblings). 
Before research, all subjects signed informed consent. 
The inclusion criteria for the case sample 
were lung cancer patients from the Batak ethnic group 
who have been diagnosed based on cytology or 
histopathology examination, male lung cancer 
patients, and smokers. On the other hand, the 
inclusion criteria for the control sample were 
individuals who did not have lung cancer matched 
with the case group according to age, sex, and Batak 
people who had a smoking history. 
The exclusion criteria for the case sample 
were lung cancer patients who consumed rifampicin, 
dexamethasone, phenobarbital, methoxsalen (8-
methoxypsoralen), tranylcypromine, tryptamine, 
coumarin, and neonatal thiol, abnormal function of 
liver and kidney, and were not undergoing 
chemotherapy while the exclusion criteria for the 
control sample were healthy individuals who did not 
consume drugs. 
The methods used in this research were 
purposive sampling and case-control study. The 
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research was conducted within a period of one year 
(November 2016 to April 2017), and it has been 
accepted by the Ethics Committee of the Faculty of 
Medicine, University of Sumatera Utara. 
Nicotine II chewing gum was obtained from 
Guardian Pharmacia (Singapore). Nicotine, cotinine 
and 3-hydroxycotinine were purchased from Sigma 
(St. Louis, Mo). Pure gene deoxyribonucleic acid 
(DNA) isolation kit was obtained from Promega 
(Madison, USA). Restriction enzymes were purchased 
from New England Biolabs (Beverly, Mass). All other 
chemicals and solvents which had the highest levels 
were available commercially.  
Blood samples from all subjects were 
collected as much as 2ml, and then stored at -80°C. 
Genomic DNA was extracted from peripheral 
lymphocytes using Puregene DNA Isolation Kit 
(Promega). The CYP2A6*1A, CYP2A6*1B, and 
CYP2A6*4A genotypes used the following primer: 
2Aex7F (5'-GRCCAAGATGCCCTACATG-3`) and 
2A6R2 (5'-AAAATGGGCATGAACGCCC-3`) [24].
 
 
 
Figure 1: (a) The CYP2A6*1A, CYP2A6*1B, and CYP2A6*4A allele 
genotypes by PCR-RFLP. The structure scheme of CYP2A7 and 
CYP2A6 gene. Dotted boxes and open boxes represented the 
CYP2A7 and CYP2A6 exon. Lines represented the introns of each 
gene. The PCR amplification was conducted with a primer pair, 
shown in horizontal arrows. The amplified DNA was triple-digested 
by Eco81I, AccII, and StuI. Restriction sites were marked with 
vertical arrows E, A, and S [33];
 
(b) Schematic polymerase PCR-
RFLP patterns for different of CYP2A6 alleles in the case group 1-5, 
M = marker, K = control, UC = uncut. The *1A/*1B, 1120, 427, 319, 
149, and 75 bp fragments (KT 01). The *1A/*1A, 1120, 427, 149, 
and 79 bp fragments (KT 02). The *1B/*1B, 1120, 319, 149, and 75 
bp fragments (KT 03). The *1A/*4A, 1120, 728, 427, 319, and 278 
bp fragments (KT 05). The *4A/*4A, 728, 319, 278, and 129 bp 
fragments (ST 08). The marker was a 1200 bp ladder marker; (c). 
Representative photograph of polymerase chain reaction-restriction 
fragment length polymorphism patterns for different CYP2A6 alleles 
of CYP2A6*1A, CYP2A6*1B, and CYP2A6*4 
 
The genomic DNA samples (0.5 µg) was 
added with PCR mixtures (25 µl) which contained 1 
PCR buffer, 1.5 mM MgCl2, 0.4 µM of each primer, 
250 µM dNTPs, and 1 U of Taq DNA polymerase. 
After initial denaturation at a temperature of 95°C for 1 
minute, the application was carried out with 
denaturation at 95°C for 15 seconds, annealing at 
60°C for 20 seconds, and extension at 72°C for 3 
minutes for 35 cycles, followed by a final extension at 
72°C for 7 minutes. The PCR product was triple-
digested with restriction enzymes, such as Eco81I, 
AccII, and StuI. The product was analysed by 
electrophoresis at 2% of agarose gel [25].
 
The 
CYP2A6*1A, CYP2A6*1B, and CYP2A6*4A allele 
genotypes obtained from PCR-RFLP, the schematic 
polymerase PCR-RFLP patterns for different of 
CYP2A6 alleles, and the representative photograph of 
PCR-RFLP patterns for different CYP2A6 alleles are 
shown in Figure 1. 
The research subjects should not smoke 
within 2 weeks to eliminate nicotine and metabolite 
from cigarettes. On the next day, after a night of 
fasting, all subjects were asked to chew nicotine gum 
(Nicotinell gum which contained 4 mg of nicotine) for 
30 minutes, and they should chew for 10 per 30 
seconds.  
Blood samples were collected from the cubital 
vein just before and two hours after started to chew, 
and these samples were stored at -20
o
C before the 
analysis. Measurement of cotinine and 3’-
hydroxycotinine (3HC) was conducted with Liquid 
Chromatography Tandem-Mass Spectrometry (LC-
MS/MS). The ratio of 3HC/cotinine was calculated as 
the nicotine metabolism index. Rubinstein et al., [26] 
state that the ratio of 3HC/cotinine for slow 
metabolizers is < 0.5 while the ratio for fast 
metabolizers is ≥ 0.5. Intraassay and interassay 
precision tests had been conducted in the LC-MS/MS 
equipment used. 
Data analysis was performed by using Epi 
Info-7 software. Conditional Logistic Regression test 
was run to assess the differences between the two 
groups on demographic factors. Also, conditional 
logistic regression test and logistic regression test 
were also run to investigate the relationship between 
CYP2A6 genotype and allele with lung cancer 
incidence and nicotine metabolism rate. The 
difference between nicotine metabolism rates and 
CYP2A6 allele types was tested with the Kruskal 
Wallis test and Mann Whitney test. Logistic regression 
test was conducted to assess the effect of the 
CYP2A6 allele on nicotine metabolism rate while 
conditional logistic regression test was conducted to 
assess the relationship between nicotine metabolism 
rate with lung cancer incidence. The ratio of nicotine 
metabolism rate (3HC/cotinine ratio) between the 
case group and the control group and its relation to 
CYP2A6 allele were analysed with the Mann Whitney 
test. P value < 0.05 was considered significant. 
 
 
Results 
 
This study involved 70 lung cancer patients in 
the case group and 70 healthy people in the control 
group. The demographic characteristics of all 
subjects, such as 5 sub-ethnics of Batak (i.e. Toba, 
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Karo, Simalungun, Mandailing, and Pak Pak), types of 
cigarette, Brinkman Index (multiplication of smoking 
duration with number of cigarette per day), types of 
cancer, and Body Mass Index (BMI) can be seen in 
Table 1.  
Table 1 shows that there was no significant 
difference in age, sub-ethnics of Batak, and the 
amount of cigarette consumption expressed in the 
Brinkman Index between the case group and the 
control group which means that these factors were not 
potentially biased in this study. The demographic 
factors which showed significant differences between 
the two groups were BMI and the types of cigarette. 
Table 1: Demographic characteristics of subjects 
  
Total 
Cases  
(n = 70) 
Control  
(n = 70) P-value 
  
N (%) n (%) n (%) 
Age 
<65 106 (75.7) 52 (74.3) 54 (77.1) 
0.69 
≥ 65 34 (24.3) 18 (25.7) 16 (22.9) 
Bataknese Sub 
ethnic 
Toba 94 (67.1) 49 (70) 45 (64.3) 
0.09 
Karo 34 (24.3) 13 (18.6) 21 (30) 
Simalungun 4 (2.9) 1 (1.4) 3 (4.3) 
Mandailing 7 (5) 6 (8.6) 1 (1.4) 
Pakpak 1 (0.7) 1 (1.4) 0 (0.0) 
BMI 
Underweight 16 (11.4) 6 (8.6) 10 (14.3) 
0.01
a Normoweight 59 (42.2) 44 (62.9) 15 (21.4) 
Overweight 29 (20.7) 10 (14.2) 19 (27.1) 
Obersity 26 (18.6) 10 (14.2) 26 (37.2) 
Type of cigarette 
Mild 29 (20.7) 10 (14.3) 19 (27.2) 
< 0.001
a 
Kretek 66 (47.1) 26 (37.1) 40 (57.1) 
Mix 45 (32.2) 34 (48.6) 11 (15.7) 
Brinkman Index 
Mild 13 (9.3) 6 (8.6) 7 (10) 
0.63 Moderate 53 (37.8) 24 (34.3) 29 (41.4) 
Severe 74 (52.9) 40 (57.1) 34 (48.6) 
Cytology/ 
histopathology 
subtype 
Squamous cell ca 5 (7.1) 5 (7.1) 0 
NA 
Adenocarcinoma 65 (92.9) 65 (92.9) 0 
a
 significant with Conditional Logistic Regression test (matched based on gender and 
Batak ethnic group); BMI (body mass index), NA (not available). 
 
 
After the PCR-RFLP was performed on all 
research subjects, data of CYP2A6 genotypes and 
alleles were obtained as shown in Table 2. The 
frequency of CYP2A6 genotypes in both groups did 
not show significant deviations from Hardy-Weinberg 
Equilibrium (p > 0.05 for the case group and the 
control group). Among 140 male Batak smokers, the 
frequencies of CYP2A6*1A, CYP2A6*1B, and 
CYP2A6*4A alleles were 44.3%, 48.9%, and 6.8%, 
respectively.  
This is quite surprising because *1A allele is 
assumed as the wildtype in most populations and 
other ethnic groups. In contrast, this study found that 
the highest number of allele found was *1B. The 
highest number of genotypes found was CYP2A6 
*1A/*1B with 37.1%, and it was followed by 
CYP2A6*1A/*1A with 24.3%.  
There was a significant difference in nicotine 
metabolism rates among the types of the CYP2A6 
allele. Although the average metabolic rate of all allele 
groups was classified into the slow metabolizer (ratio 
of 3HC/cotinine ≤ 0.5), the *1B allele showed the 
highest metabolic rate compared to other alleles, 
which was 3 times higher than the *4A allele and 1.5 
times higher than the *1A allele. 
Table 2: Frequency of CYP2A6 genotype and allele and its 
relation to nicotine metabolism rate 
Genotype 
Subjects* 
n % 
CYP2A6 *1A/*1A 34 24.3 
CYP2A6 *1A/*1B 52 37.1 
CYP2A6 *1B/*1B 42 30 
CYP2A6 *1A/*4A 4 2.9 
CYP2A6 *4A/*4A 8 5.7 
Allele 
Subjects* 
3HC/cotinine Ratio
d
 
n % 
CYP2A6 *1A 124 44.3 0.14 ± 0.31               b 
CYP2A6 *1B 137 48.9 0.21 ± 0,37     a 
CYP2A6 *4A 19 6.8 0.07 ± 0.21                      c 
*
All frequencies of CYP2A6 genotypes were in Hardy-Weinberg equilibrium; 
a
 p < 0.001 
with Kruskal Wallis test; 
b
p = 0.02 with Mann Whitney U test; 
c 
p < 0.001 with Mann 
Whitney U test; 
d
 data are expressed in mean ± standard deviation. 
 
To investigate the association between 
CYP2A6 genotype and allele with lung cancer 
incidence and nicotine metabolism rate, a cross-
tabulation was conducted as shown in Table 3. 
Nicotine metabolism rate was measured using a 
3HC/cotinine ratio parameter in serum, and it was 
measured 2 hours after the administration of nicotine 
gum. A ratio value of 3HC/COT < 0.5 was classified 
as slow metabolizer while a value ≥ 0.5 was classified 
as fast metabolizer. 
Table 3 shows that there was no significant 
relationship between CYP2A6 genotype and an allele 
with lung cancer incidence and nicotine metabolism 
rate (P > 0.05). One interesting point was that almost 
all subjects were classified as slow metabolizers, and 
only 13 people (18.6%) were classified as fast 
metabolizers. Based on Table 3, individuals with 
CYP2A6*1B allele were 2.07 times more likely to be 
fast metabolizer if compared with the *1A allele 
(wildtype). In contrast, individuals with *4A allele were 
more likely to be slow metabolizer although this 
relationship was not statistically significant. These 
findings are in line with the data shown in Table 4 
which states that the *1B allele has the highest 
3HC/cotinine ratio compared to the other alleles. 
Table 3: Association of CYP2A6 genotype and allele with lung 
cancer incidence and nicotine metabolism rate 
    Lung Cancer 
P-value 
Nicotine Metabolism P- 
value 
OR 95% CI 
  
Case Control Fast Slow 
CYP2A6 
Genotype 
*1A/*1A 15 (21.4) 19 (27.1) 
0.374
a 
0(0) 34 (26.5) 
0.142
b 
NA
c 
NA 
*1A/*1B 30 (42.8) 22 (31.4) 7(53.8) 45 (35.1) 
*1B/*1B 21 (30) 21 (30) 5(38.5) 37 (28.9) 
*1A/*4A 2 (2.9) 2 (2.9) 1(7.7) 3(2.3) 
*4A/*4A 2 (2.9) 6 (8.6) 0 (0) 8 (6.2) 
Total 
70 (100) 70 (100)  
13 
(100) 127 (100)  
  
CYP2A6 
Allele 
*1A 62 (44.3) 62 (44.3) 
0.187
a 
8(30.8) 116(45.7) 
0.19
b 
1
d 
1 
*1B 
72 (51.4) 65 (46.4) 
17(65.4
) 120(47.2) 
2.07 0.8-4.9 
*4A 6 (4.3) 13 (9.3) 1 (3.8) 18 (7.1) 0.76 0.09-6.45 
Total 
140 (100) 140 (100) 
 
26 
(100) 254 (100) 
 
  
a
 Conditional Logistic Regression test with matched gender and Batak ethnic group; 
b
 Logistic Regression 
test; 
c
 OR not available; 
d
 Reference value. 
 
 
 
Theoretically, individuals who are fast 
metabolizers will inhale more nicotine in cigarettes, 
and thereby increase the risk of lung cancer 
incidence. Surprisingly, this study found the opposite. 
Individuals who were slow metabolizers were 5.49 
times more likely to develop lung cancer than fast 
metabolizers (95% CI 1.2 – 24.8; P = 0.01), as shown 
in Table 4. The difference in nicotine metabolism rate 
between the case group and the control group and its 
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relationship with CYP2A6 allele can be seen in Figure 
2.  
Table 4: Association of nicotine metabolism rate with lung 
cancer incidence 
Nicotine Metabolism 
Cancer Control 
P - value OR 
n (%) n (%) 
Fast metabolizer 2 (2.9) 11 (15.7) 
0.01
a
 
1
b
 
Slow Metabolizer 68 (97.1) 59 (84.3) 5.49 (1.2-24.8) 
Total 70 (100) 70 (100) 
  a Significant with Conditional Logistic Regression test; 
b 
Reference value. 
 
Figure 2 showed that there was no significant 
difference in the level of nicotine, cotinine, and 3HC 
(OH-cotinine) in plasma based on CYP2A6 allele 
types in both groups (the cancer group and the 
control group). It indicates that the influence of 
CYP2A6 allele lies in the nicotine metabolism rate of 
the subjects (3HC/cotinine ratio), but it does not affect 
the rate of nicotine absorption in the body. 
 
Figure 2: Comparison of nicotine metabolism rate (3HC/cotinine 
ratio) between the case group and the control group and its 
relationship with CYP2A6
a
 allele. There was a significant difference 
in the level of 3HC/cotinine ratio between the case group and the 
control group (P < 0.001 with Mann Whitney test) 
 
 
Discussion 
 
In this study, the age range of lung cancer 
patients as the research subjects was 40-64 years. 
This based on the research conducted by Mong et al., 
[27]
 
that found that the age of most lung cancer 
patients was over 60 years ( 51.4%) because 
exposure to carcinogenic substances took a long time 
to cause an imbalance between oncogene function 
and tumor suppressor gene in the growth process of 
cancer cells, whereas lung cancer found at a young 
age or below the age of 50 years was associated with 
genetic factor or started smoking at a young age [28]. 
The ethnic group studied was Batak as the 
population of research subjects. In addition to the pure 
genetic inheritance in Batak, Batak society in North 
Sumatra has been accustomed to cigarettes, including 
mild cigarettes, kretek, and white cigarettes. 
Therefore, social environment is highly influential on 
the smoking behaviour of Batak ethnicity because 
smoking has an important element in various 
processes of customary activities. Furthermore, 
cigarettes must be provided along with food and 
beverages in every series of traditional event. After 
the traditional event finishes, cigarettes which are not 
consumed will be taken back by the event owner. 
Teenagers and children will usually hide 1-2 
cigarettes, and then the cigarettes will be consumed 
alone furtively or together with their friends. This 
causes Batak children to have been accustomed to 
consuming cigarettes since young age [29]. 
Regarding smoking and different types of 
cigarette, this study also found that the most common 
lung cancer found, adenocarcinoma is considered to 
have a relation to the type of cigarette consumed. This 
based on the study that mentions that previously the 
most common type of cytology/histopathology of lung 
cancer was the squamous cell carcinoma; however, in 
recent decades, adenocarcinoma has been the most 
prevalent type of lung cancer. This might occur 
because of the interest change in the type of cigarette 
consumed [30].
 
Thus, in the case of Batak population, 
kretek, which was discovered to be more popular than 
mild cigarettes contains cloves which make smokers 
inhale more deeply, so the cigarette smoke will pass 
through small respiratory tracts which will make them 
exposed to more carcinogens [31]. Besides, Thun et 
al. [32] state that higher levels of nitrate contained in 
the tobacco mixture are also associated with the 
development of adenocarcinoma type of cancer cells. 
Stellmann et al., [33]
 
also state that extremely high 
levels of nitrosamines in the peripheral respiratory 
tract would trigger the occurrence of cell changes into 
adenocarcinoma. Thus, those results are also by the 
fact that tobacco-specific N-nitrosamines (TSNAs) 
induce adenocarcinoma type of lung cancer [34]. 
Interindividual variation associated with lung 
cancer risk is determined by uptake variation and 
metabolism of carcinogenic tobacco substances. The 
uptake of carcinogenic substances is related to the 
uptake of nicotine (the addictive component of 
tobacco). Previous research has found that pulmonary 
tumorigenesis can be triggered by the anti-apoptotic 
effect of cotinine through the activation of PI3K/Akt 
pathway mediated by CYP2A6 [35]. CYP2A6 in 
smokers is the main enzyme in nicotine metabolism. 
Nicotine will be metabolized into cotinine (COT), and 
COT will be metabolized into trans-3-hydroxycotinine 
(3HC) with the help of CYP2A6 enzymes. If the 
smoker is a slow metabolizer of nicotine, he only 
smokes a few cigarettes; thus, the level of exposure to 
carcinogenic materials will be low. Also, it is also 
reported that plasma cotinine concentrations, which 
are the main metabolite of nicotine, play an important 
role in the development of lung cancer incidence [36].
 
In the wildtype of CYP2A6, the risk of lung cancer 
incidence will increase. However, if gene deletion 
CYP2A6*4 allele is found, it can reduce lung cancer 
incidence. 
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The most common CYP2A6 allele in both 
groups in this study was *1B. CYP2A6*1B gene allele 
gives a high metabolic index, faster than the effect of 
*1A allele. Oscarson et al., [22] which discovered the 
frequency of CYP2A6*1B allele was 30.0% in 
Caucasians (Spaniards) and 40.6% in Asian 
(Chinese) populations, found that the CYP2A6 genetic 
polymorphism might be associated with lung cancer in 
the American and Asian populations, but it is not the 
same for the Caucasian population. This suggests 
that different ethnic will result in a different relationship 
between the two. In Batak ethnic population, the *1B 
allele was found about 48.9% higher than some other 
research population, but no significant relationship 
was found between CYP2A6 genotype and allele with 
lung cancer incidence (P > 0.05). A different result 
was found by Fujieda et al., [16] which stated that 
CYP2A6 is not only one of the major determinants 
which do affect not only smoking behaviour, but also 
individual’s susceptibility to lung cancer for Japanese 
Men population. 
Several studies have also investigated the 
relationship between deleted polymorphisms, 
CYP2A6*4, and the risk of lung cancer in different 
populations. However, the results are inconsistent. 
One study in Japan reported a 50% reduction in 
cancer risk related to CYP2A6*4 statistically while a 
similar study in China found a twofold increase in lung 
cancer risk in individuals with CYP2A6*4. Several 
meta-analyses reported a statistically significant 50% 
lower crude odds ratio in lung cancer with slow 
metabolizer smokers in the Asian populations. By our 
results, CYP2A6*4 was associated with an 
approximately 30% decreased the risk of lung cancer 
[18]. 
The results of this study showed that there 
was no significant relationship between CYP2A6 
genotype and allele with nicotine metabolism rate (P > 
0.05). One interesting thing found in this study was 
that almost all subjects were classified as slow 
metabolizers, and only 13 people (18.6%) were 
classified as fast metabolizers. However, there was a 
significant difference in nicotine metabolism rates 
among the types of the CYP2A6 allele. The average 
metabolic rate of all allele groups was classified as the 
slow metabolizer (3HC/cotinine ratio ≤ 0.5), but the 
*1B allele showed the highest metabolic rate 
compared to other alleles, which was 3 times higher 
than the *4A allele and 1.5 times higher than the *1A 
allele. The *1B allele tends to be a fast metabolizer 
than the *4A allele. Over 20 years ago, individuals 
who metabolised nicotine poorly would smoke fewer 
cigarettes a day or less intense per cigarette than 
smokers who metabolised nicotine more efficiently 
[18].
 
This poor metabolism will tend to develop lung 
cancer because of its lower exposure to carcinogens 
in nicotine through the smoke. Several studies have 
reported that smokers who carry a lack of activity or 
less CYP2A6 allele would smoke less. However, only 
in the Asian populations, both Japanese and Chinese, 
which have a high genetic variant prevalence, have an 
association between CYP2A6, smoking dose, and 
lung cancer. Theoretically, individuals who are fast 
metabolizers will inhale more nicotine in cigarettes, 
and thereby increase the risk of developing lung 
cancer. Surprisingly, this study found the opposite. 
Individuals who were slow metabolizers were 5.49 
times more likely to develop lung cancer than the fast 
metabolizers (95% CI 1.2 – 24.8; P = 0.01). Based on 
the above explanation, the relationship between 
genetic polymorphisms of CYP2A6 with nicotine 
metabolism and the risk of developing lung cancer in 
Batak population was found to have different results 
from different populations and races. Therefore, 
further research is important to investigate the 
differences in other populations and races.  
In conclusion, CYP2A6 activities signified the 
need for more cigarettes to maintain the levels and 
the metabolism of nicotine. The most common 
CYP2A6 allele in the two groups was *1B. The results 
showed that no significant relationship was found 
between CYP2A6 and nicotine metabolism in lung 
cancer patients. It was also found that the *1B allele 
was more likely to be a slow metabolizer than the *1A 
allele. 
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